← Human Trials & Peer-Reviewed Studies
Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL
Plain-language guide to PMID 42102896 (2026): double-blind randomized controlled trial of Exenatide in 14,752 adults.
Key Facts
- PMID
- 42102896
- Journal
- American heart journal
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Kittipibul V et al. (9 authors)
- DOI
- 10.1016/j.ahj.2026.107475
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exenatide, published as a randomized controlled trial.
The researchers evaluated the prognostic value of baseline and 1-year changes in N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (cTnI), and whether baseline biomarker concentrations modified exenatide effects.
Who Took Part
According to the abstract, 14,752 adults were involved.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
In a biomarker cohort, 4,292 participants had serial NT-proBNP or cTnI at baseline and 1 year.
Treatment interaction was tested with biomarker by treatment terms.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The adults were allocated by chance, so the Exenatide group and the comparison group should start out alike.
As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.
What Was Measured
The researchers evaluated the prognostic value of baseline and 1-year changes in N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (cTnI), and whether baseline biomarker concentrations modified exenatide effects.
PubMed files the paper under topics including Diabetes Mellitus, Type 2, Peptide Fragments, Natriuretic Peptide, Brain, Biomarkers, Troponin I, Exenatide and Glucagon-Like Peptide-1 Receptor Agonists.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 14,752 adults.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2026 (American heart journal), a journal based in United States.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.